For this purpose, patients with prostate cancer who presented biochemical recurrence (no evidence of cancer on radiographic scans but with rising prostate-specific antigen (PSA) levels) were recruited and treated with 5-AZA and ATRA. This evidence concerns the gene KLK3 and prostate carcinoma.